Scynexis (SCYX) Net Income Growth (3y) (2017 - 2026)
Scynexis (SCYX) Net Income Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.21 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -62.58% |
| 5 | United Therapeutics | 23.06 Bn | 20.91 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.25 Bn | 18.44 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.48 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -17.90% |
| 10 | Scynexis | 23.44 Mn | -13.31 Mn | - | 21.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.43% |
| Dec 31, 2025 | 38.01% |
| Sep 30, 2025 | 33.78% |
| Jun 30, 2025 | 19.80% |
| Mar 31, 2025 | 0.37% |
| Dec 31, 2024 | 46.50% |
| Sep 30, 2024 | -66.81% |
| Jun 30, 2024 | -120.50% |
| Mar 31, 2024 | 27.81% |
| Dec 31, 2023 | 14.12% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | 176.59% |
| Mar 31, 2023 | -69.13% |
| Dec 31, 2022 | -12.92% |
| Sep 30, 2022 | -55.02% |
| Jun 30, 2022 | -16.67% |
| Mar 31, 2022 | 23.51% |
| Dec 31, 2021 | -48.38% |
| Sep 30, 2021 | 61.93% |
| Jun 30, 2021 | 31.16% |